Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Affymax Inc.

Company price
0.0008 USD 0.00(0%)
Last update at 2026-11-19T21:00:00Z
VOLUME
6000
Market Cap
0.06M

Momentum Score

…

Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.00
Low
0.04
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Affymax Inc. is a small publicly traded company in the biopharmaceutical sector; current public disclosures provide limited detail on its active product portfolio or operating strategy. Long-term growth could depend on progression of any development-stage programs, successful licensing or partnerships, and execution of a sustainable financing plan, which may benefit investors if realized.
Major risks include typical biotech development and regulatory failure, high cash burn with likely dilution from future financings, limited liquidity and trading volume as a Pink-listed issuer, and strong competition in drug development.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.04M
Revenue Per Share
0.00
Gross Profit TTM
0.21M
Debt / Equity
1.07
ROE
111.59%
Net Debt
-5.60M
ROCE
2660.78%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2013-12-31 2012-12-31 2011-12-31 2010-12-31 2009-12-31
Type yearly yearly yearly yearly yearly
Date 2013-12-31 2012-12-31 2011-12-31 2010-12-31 2009-12-31
Income before tax -16.58M -93.44M -61.37M -14.07M -77.94M
Net income -14.42M -93.41M -61.37M -14.07M -76.53M
Selling general administrative 27.53M 89.71M 31.88M 33.33M 36.72M
Gross profit 1.37M 49.41M 47.72M 112.52M 114.90M
Ebit -38.00M -93.95M -61.24M -16.39M -78.01M
Ebitda -37.27M -91.96M -59.05M -14.17M -75.89M
Depreciation and amortization 0.72M 1.99M 2.18M 2.21M 2.12M
Operating income -15.05M -92.04M -61.41M -14.45M -78.94M
Other operating expenses 39.39M 186.41M 109.13M 126.97M 193.84M
Interest expense 1.56M 1.44M 0.14M 0.14M 0.10M
Non recurring 20.48M 44.96M 44.96M - -
Income tax expense -2.16M -0.03M 0.00M 0.00M -1.41M
Total revenue 1.37M 94.37M 47.72M 112.52M 114.90M
Total operating expenses 39.39M 141.45M 109.13M 126.97M 193.84M
Cost of revenue 11.86M 44.96M 75.33M 93.64M 191.72M
Total other income expense net 22.98M -0.03M 0.01M 0.24M 0.17M
Net income from continuing ops -14.42M -93.41M -61.37M -14.07M -
Net income applicable to common shares -14.42M -93.41M -61.37M -14.07M -
Breakdown 2013-12-31 2012-12-31 2011-12-31 2010-12-31 2009-12-31
Type yearly yearly yearly yearly yearly
Date 2013-12-31 2012-12-31 2011-12-31 2010-12-31 2009-12-31
Total assets 7.44M 118.22M 119.00M 131.39M 211.51M
Other current assets 0.72M 3.07M 0.69M 0.45M 10.14M
Total liab 8.87M 109.94M 43.00M 58.84M 144.60M
Total stockholder equity -1.43M 8.28M 76.00M 72.55M 66.91M
Deferred long term liab - - 5.17M - -
Other current liab 8.77M 83.64M 18.82M 28.80M 104.19M
Common stock 0.04M 0.04M 0.04M 0.03M 0.02M
Retained earnings -558.14M -543.71M -450.30M -388.93M -374.86M
Other liab - 10.86M 22.70M 11.22M 10.88M
Other assets 1.12M 10.40M 8.36M 7.99M 7.32M
Cash 5.60M 68.27M 54.34M 63.50M 125.30M
Total current liabilities 8.87M 99.08M 19.77M 47.62M 133.72M
Current deferred revenue - 55.37M - 18.50M 71.97M
Net debt -5.60M -59.42M -54.34M -63.50M -116.10M
Short term debt - 8.84M - - 9.19M
Short long term debt - 8.84M - - -
Short long term debt total - 8.84M - - 9.19M
Other stockholder equity 556.67M 551.96M 526.24M 461.43M 441.80M
Property plant equipment - 2.98M 3.01M 3.98M 5.47M
Total current assets 6.32M 102.51M 107.62M 99.54M 190.74M
Long term investments - 2.32M - 19.88M -
Net tangible assets -1.43M 8.28M 76.00M 72.55M -
Short term investments - 9.72M 44.16M 33.58M 35.29M
Net receivables - 18.36M 6.94M - 20.00M
Inventory - 3.09M - - -
Accounts payable 0.10M 6.59M 0.94M 0.32M 0.46M
Accumulated other comprehensive income - -0.00M 0.02M 0.03M -0.06M
Non currrent assets other 1.12M 3.53M 1.48M 1.19M 1.53M
Non current assets total 1.12M 15.71M 11.38M 31.84M 20.77M
Breakdown 2013-12-31 2012-12-31 2011-12-31 2010-12-31 2009-12-31
Type yearly yearly yearly yearly yearly
Date 2013-12-31 2012-12-31 2011-12-31 2010-12-31 2009-12-31
Investments 13.18M 32.03M 9.22M -10.75M -
Change to liabilities -6.49M 18.24M -6.58M -53.62M 14.31M
Total cashflows from investing activities 14.40M 28.00M 8.00M -11.48M 49.19M
Net borrowings -10.00M 10.00M 10.00M -9.19M -
Total cash from financing activities -9.73M 23.11M 54.80M -1.08M 132.98M
Change to operating activities -29.88M -6.96M -9.52M -16.07M -
Net income -14.42M -93.41M -61.37M -14.07M -76.53M
Change in cash -62.67M 13.93M -9.16M -61.80M 101.25M
Begin period cash flow 68.27M 54.34M 63.50M 125.30M 24.05M
End period cash flow 5.60M 68.27M 54.34M 63.50M 125.30M
Total cash from operating activities -67.34M -37.18M -71.97M -49.23M -80.93M
Depreciation 0.72M 1.99M 2.18M 2.21M 2.12M
Other cashflows from investing activities 1.23M -2.48M 0.04M - -
Change to inventory - -4.51M -4.51M -4.51M -
Change to account receivables 18.36M -15.53M -6.94M 18.56M 3.13M
Sale purchase of stock 0.27M 13.11M 54.80M 8.11M -0.00M
Other cashflows from financing activities 0.27M 10.00M 8.00M -11.48M 9.19M
Change to netincome -33.48M 57.10M 10.23M 12.31M -
Capital expenditures 0.00M 4.06M 1.26M 0.73M 0.72M
Change in working capital -20.16M -2.85M -22.87M -49.55M -17.68M
Stock based compensation 4.44M 11.21M 10.03M 11.52M 11.17M
Other non cash items -37.92M 45.89M -61.30M 0.65M -0.01M
Free cash flow -67.34M -41.24M -73.23M -49.96M -81.64M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
AFFY
Affymax Inc.
-
-%
0.00 - - 1.43 0.56 -0.17
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 36.06

Profile*

Affymax Inc.

Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.

630 Fifth Avenue, New York, NY, United States, 10020

650 812 8700

2

Name Title Year Born
Mr. Mark G. Thompson CFO & Sec. 1962
Mr. Jonathan M. Couchman CEO, Pres & Director 1970
Dr. Tracy J. Dunn Ph.D., J.D. VP of Intellectual Property & Legal Affairs 1963
Mr. Mark G. Thompson CFO & Secretary 1962
Mr. Jonathan M. Couchman CFA CEO, President & Director 1970
Dr. Tracy J. Dunn Ph.D., J.D. Vice President of Intellectual Property & Legal Affairs 1963

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…